Genetic variations of DNA repair genes and their prognostic significance in patients with acute myeloid leukemia

Common genetic variations in genes involved in DNA repair or response to genotoxic stress may influence both cancer susceptibility and treatment response individually or interactively. However, in acute myeloid leukemia (AML), the relevance of these genetic variations remains to be fully established. In this study, we analyzed 42 genetic variations among 15 candidate genes in 307 AML patients and 560 age‐sex matched controls. Their associations with chemotherapy response were further evaluated in combination with other well‐established prognostic factors. An increased risk of AML was found in individuals heterozygous for XPD 2251A>C (rs13181) with an odds ratio (OR) of 1.637 (95% confidence interval [CI]: 1.118–2.395), and the increased risk could be attributed to C allele (OR = 1.505, 95% CI: 1.061–2.134). Postchemotherapy response analysis revealed that AML patients heterozygous for ATM 4138C>T (rs3092856) or GG homozygous for TP53 215C>G (rs1042522) were independently linked to inferior treatment outcomes. These results uncover novel prognostic factors for AML patients treated with chemotherapy and may also indicate an etiological role of XPD in this disease.

[1]  P. Bolufer,et al.  Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. , 2006, Leukemia research.

[2]  Ananya Choudhury,et al.  Analysis of variants in DNA damage signalling genes in bladder cancer , 2008, BMC Medical Genetics.

[3]  M. Vignetti,et al.  Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation , 2009, Haematologica.

[4]  Alexandra G. Smith,et al.  Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. , 2004, Blood.

[5]  Arto Mannermaa,et al.  RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. , 2005, Carcinogenesis.

[6]  M. Nakanishi,et al.  Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease. , 2004, Blood.

[7]  M. Gobbi,et al.  The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients , 2001, Leukemia.

[8]  J. Downing,et al.  Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.

[9]  D. Christiansen,et al.  Genetics of therapy-related myelodysplasia and acute myeloid leukemia , 2008, Leukemia.

[10]  Y. Shiloh,et al.  Interaction between ATM protein and c-Abl in response to DNA damage , 1997, Nature.

[11]  T. Naoe,et al.  Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia , 2000, European journal of haematology.

[12]  K. Fidelis,et al.  Functional characterization of Ape1 variants identified in the human population. , 2000, Nucleic acids research.

[13]  R. Schneider-Stock,et al.  Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. , 2004, The American journal of pathology.

[14]  A. Ashworth,et al.  Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. , 2007, Human molecular genetics.

[15]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[16]  H. Kantarjian,et al.  A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. , 1996, Blood.

[17]  Irene M. Leigh,et al.  Role of a p53 polymorphism in the development of human papilloma-virus-associated cancer , 1998, Nature.

[18]  Y. Liang,et al.  AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2 , 2009, Leukemia.

[19]  Eula Bingham,et al.  NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: A HuGE review , 2002, Genetics in Medicine.

[20]  Jiong Hu,et al.  Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. , 2004, Pharmacogenetics.

[21]  P. Rosenberg,et al.  Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry , 2008, Haematologica.

[22]  J. Esteve,et al.  Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies , 2007, Leukemia.

[23]  Yuntao Xie,et al.  p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer , 2005, Clinical Cancer Research.

[24]  T. Alonzo,et al.  XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report. , 2006, Blood.

[25]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[26]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Julian Peto,et al.  Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 first-degree relatives. , 2006, Human molecular genetics.

[28]  Concordance of Pharmacogenetic Polymorphisms in Tumor and Germ Line DNA in Adult Patients with Acute Myeloid Leukemia , 2007, Cancer Epidemiology Biomarkers & Prevention.

[29]  B. Gusterson,et al.  p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. , 2003, Cancer cell.

[30]  F. Clavel-Chapelon,et al.  Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[32]  D. Hunter,et al.  Genetic association and functional studies of major polymorphic variants of MGMT. , 2007, DNA repair.

[33]  Fan Wang,et al.  DNA Repair Gene XPD Polymorphisms and Cancer Risk: A Meta-analysis Based on 56 Case-Control Studies , 2008, Cancer Epidemiology Biomarkers & Prevention.